ANI Pharmaceuticals
ANIP
ANIP
126 hedge funds and large institutions have $330M invested in ANI Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 33 increasing their positions, 50 reducing their positions, and 10 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding in top 10
Funds holding in top 10: →
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
1.61% more ownership
Funds ownership: 57.3% → 58.92% (+1.6%)
34% less repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 50
58% less call options, than puts
Call options by funds: $726K | Put options by funds: $1.72M
Holders
126
Holding in Top 10
2
Calls
$726K
Puts
$1.72M
Top Buyers
| 1 | +$6.58M | |
| 2 | +$5.8M | |
| 3 | +$4.47M | |
| 4 |
WCM
Wedge Capital Management
Charlotte,
North Carolina
|
+$4.17M |
| 5 |
GACM
Global Alpha Capital Management
Montreal,
Quebec, Canada
|
+$3.07M |
Top Sellers
| 1 | -$4.31M | |
| 2 | -$2.03M | |
| 3 | -$1.72M | |
| 4 |
Goldman Sachs
New York
|
-$1.39M |
| 5 |
Fuller & Thaler Asset Management
San Mateo,
California
|
-$1.38M |